Here's Why TG Therapeutics Rose as Much as 36.7% Today
Shares of TG Therapeutics (NASDAQ: TGTX) gained as much as 36.7% after the company announced an update for two triple-combination therapies it's developing as treatments for relapsed/refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). The clinical-stage company presented the data at the Annual Meeting of the American Society of Hematology (ASH).
Both triple combinations provoked robust responses in the difficult-to-treat cancers. In fact, one achieved an objective response rate (ORR) of 100%, which means all patients responded to treatment. The results are early and from a small number of patients, but they sure are promising.
As of 1:38 p.m. EST, the pharma stock had settled to a 24% gain.
Source Fool.com
